NOVEL_MYOKINE

Irisin - a novel myokine protective against metabolic disease

 Coordinatore KAROLINSKA INSTITUTET 

Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 1˙999˙433 €
 EC contributo 1˙999˙433 €
 Programma FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call ERC-2012-StG_20111109
 Funding Scheme ERC-SG
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-01-01   -   2017-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Dr.
Nome: Pontus
Cognome: Almer Boström
Email: send email
Telefono: +46 8 52486979
Fax: +46 8 339380

SE (STOCKHOLM) hostInstitution 1˙999˙433.00
2    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Mrs.
Nome: Riitta
Cognome: Ljungström
Email: send email
Telefono: +46 8 52487321
Fax: +46 8 339380

SE (STOCKHOLM) hostInstitution 1˙999˙433.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

conserved    therapeutic    fat    mice    ucp    diabetes    tissues    diseases    expenditure    cardiovascular    muscle    exercise    protein    energy    irisin    disease   

 Obiettivo del progetto (Objective)

'Cardiovascular disease and diabetes constitute the major disease burden in the western world with growing morbidity. Exercise is known to ameliorate many of the key processes in the pathogenesis of these diseases, but the underlying mechanism is not clear. Especially little is known about how exercise affects non-muscle tissues such as the heart, fat and liver. Knowledge of such pathways could lead to new therapeutic possibilities for diabetes and cardiovascular diseases. I have recently discovered a new hormone, named Irisin. Irisin is regulated by PGC1α, secreted from muscle to plasma after exercise and promotes the formation of brown fat via an unknown receptor. Furthermore, irisin is 100% conserved between mice and humans at the amino acid level (89% identity between zebfrafish and human). Nanomolar levels of this protein increase uncoupling protein 1 (UCP1) in cultures of primary white fat cells by 50 fold or more, resulting in very large increases in uncoupled respiration. Perhaps more remarkable, in vivo delivery of irisin stimulates a robust increase in UCP1, increased energy expenditure and reversal of type II diabetes in high fat fed mice. It is thus likely that irisin is responsible for at least some of the beneficial effects of exercise on the browning of adipose tissues and increases in energy expenditure. The therapeutic potential of irisin is obvious; it is a conserved endogenous polypeptide, induced with exercise and with powerful anti-diabetic properties. Irisin could, for example, be administered exogenously, or the secretion of irisin could be enhanced. These approaches, however, require additional studies, and my aim in this project is to advance the knowledge around irisin for future therapeutic testing. Given success of the ERC grant application, I will move from Harvard/Boston 2012 and start my lab at the department of Cell- and Molecular Biology, Karolinska Institute, Sweden. As seen in my list of publication, Im well prepared for this task'

Altri progetti dello stesso programma (FP7-IDEAS-ERC)

MISTIC (2011)

Mastering the dusty and magnetized Interstellar Screen to Test Inflation Cosmology

Read More  

GENECADD (2011)

GEnetic NEtworks as a tool for anti-CAncer Drug Development

Read More  

FUNDMS (2009)

Functionalisation of Diluted Magnetic Semiconductors

Read More